Status:
COMPLETED
Assessing the Impact of Control-IQ Technology
Lead Sponsor:
Children's Hospital of Eastern Ontario
Collaborating Sponsors:
Tandem Diabetes Care, Inc.
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
6-18 years
Brief Summary
This is a single-centre, mixed-methods, prospective study in pediatric patients with T1D initiating Control-IQ technology on the Tandem t-slim X2 insulin pump. Primary Objective: To determine pediat...
Detailed Description
Background Information \& Rationale The management of type 1 diabetes (T1D) is rapidly evolving to offer technology that aims to improve metabolic control and decrease the burden of diabetes manageme...
Eligibility Criteria
Inclusion
- Diagnosis of T1D
- Age 6-18 years
- Currently using the Tandem t:slim X2 insulin pump with Dexcom G6 CGM, who are initiating Control-IQ
Exclusion
- Patients under the age of 6 years of age
- Patients who are not English or French speaking
- Patients unwilling to provide consent (assent where applicable).
Key Trial Info
Start Date :
March 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 26 2021
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04838561
Start Date
March 15 2021
End Date
October 26 2021
Last Update
January 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada, K1H8L1